First Dallas Securities Inc. Acquires 838 Shares of Novo Nordisk A/S (NYSE:NVO)

First Dallas Securities Inc. grew its holdings in Novo Nordisk A/S (NYSE:NVO) by 17.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,654 shares of the company’s stock after acquiring an additional 838 shares during the quarter. First Dallas Securities Inc.’s holdings in Novo Nordisk A/S were worth $486,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Caas Capital Management LP grew its position in Novo Nordisk A/S by 52.8% in the 4th quarter. Caas Capital Management LP now owns 11,000 shares of the company’s stock worth $946,000 after purchasing an additional 3,800 shares during the last quarter. abrdn plc lifted its stake in shares of Novo Nordisk A/S by 12.0% in the fourth quarter. abrdn plc now owns 260,169 shares of the company’s stock valued at $22,304,000 after buying an additional 27,784 shares during the period. Fourpath Capital Management LLC grew its position in Novo Nordisk A/S by 10.2% during the fourth quarter. Fourpath Capital Management LLC now owns 3,306 shares of the company’s stock worth $284,000 after buying an additional 306 shares in the last quarter. Optas LLC increased its stake in Novo Nordisk A/S by 10.9% during the fourth quarter. Optas LLC now owns 6,259 shares of the company’s stock valued at $538,000 after acquiring an additional 614 shares during the period. Finally, Financial Life Planners acquired a new position in Novo Nordisk A/S in the 4th quarter valued at approximately $51,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. BMO Capital Markets lowered their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $82.64 on Tuesday. The stock has a market capitalization of $370.85 billion, a price-to-earnings ratio of 26.74, a P/E/G ratio of 0.93 and a beta of 0.45. The firm’s 50-day moving average price is $93.56 and its two-hundred day moving average price is $112.87. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.